SCHEMBL15491237

SCHEMBL15491237

Cc1cncc(C(C)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.38
SLC22A12 Q96S37 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
ATM Q13315 1/20 0.34
CYP2A6 P11509 3/20 0.33
PGK1 P00558 1/20 0.32
PGK2 P07205 1/20 0.32
CYP11B1 P15538 6/20 0.32
CYP11B2 P19099 6/20 0.32
CYP19A1 P11511 3/20 0.31
CYP2C9 P11712 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21958802 0.86 HCAR2 (0.38) HCAR2SLC22A12GRIN1GRIN2BATM
SCHEMBL1310273 0.84 HCAR2 (0.39) HCAR2SLC22A12ATMCYP11B1CYP11B2
SCHEMBL29427136 0.84 HCAR2 (0.39) HCAR2SLC22A12ATMCYP11B1CYP11B2
SCHEMBL2739663 0.81 HCAR2 (0.40) HCAR2SLC22A12ATMCYP2A6CYP11B1
SCHEMBL26069685 0.79 HCAR2 (0.37) HCAR2SLC22A12ATMPGK1PGK2
SCHEMBL19370439 0.79 GABRA1 (0.37)
SCHEMBL7939338 0.77 CYP11B2 (0.46) HCAR2ATMCYP11B1CYP11B2CYP19A1
SCHEMBL19310947 0.77 HCAR2 (0.38) HCAR2SLC22A12ATMCYP2A6CYP11B1
SCHEMBL22303443 0.77 HCAR2 (0.34) HCAR2SLC22A12ATMCYP2A6
SCHEMBL16755475 0.76 CYP19A1 (0.38) HCAR2GRIN1GRIN2BCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3430005-B1 COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE PLEXXIKON INC (US) 2021-12-08 EP disclosed
WO-2021057975-A1 MUTANT IDH2 INHIBITOR AND APPLICATION THEREOF 贝达药业股份有限公司 2021-04-01 WO disclosed
WO-2020249792-A1 SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 WO disclosed
WO-2020163554-A1 IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2020-08-13 WO disclosed
US-RE46630-E1 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity BOEHRINGER INGELHELHEIM INTERNATIONAL GMBH (DE) 2017-12-12 US disclosed
US-20170267660-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2017-09-21 US disclosed
US-20170073354-A1 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-03-16 US disclosed
US-9102624-B2 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2015-08-11 US disclosed
US-20140057916-A1 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267660-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PRKAR2B, AKT3, MAP3K11 HCAR2 1464/4885SLC22A12 4416/4885GRIN1 957/4885
US-20170073354-A1 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS PREP, CTSZ, PEPD HCAR2 2996/4885SLC22A12 3524/4885GRIN1 2945/4885
US-20140057916-A1 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY SERPINB1, ELANE, SERPINB6 HCAR2 3577/4885SLC22A12 3481/4885GRIN1 4302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.